Skip to Content
MilliporeSigma
All Photos(1)

Documents

D-029

Supelco

Digoxin solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)
Empirical Formula (Hill Notation):
C41H64O14
CAS Number:
20830-75-5
Molecular Weight:
780.94
MDL number:
MFCD00003674
UNSPSC Code:
41116107
PubChem Substance ID:
329798597
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]3[C@@H](O)C[C@@H](O[C@@H]3C)O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4

InChI

1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1

InChI key

LTMHDMANZUZIPE-PUGKRICDSA-N

Gene Information

human ... ATP1A1(476) , ATP1A2(477) , ATP1A3(478) , ATP1A4(480) , ATP1B1(481) , ATP1B2(482) , ATP1B3(483) , FXYD2(486)

Related Categories

General description

Digoxin is a cardiac glycoside used to treat a variety of heart conditions from atrial fibrilation to heart failure. The drug is sold under the trade names Lanoxin®, Digitek®, or Lanoxicamps. This analytical reference standard is suitable for use in LC/MS or GC/MS applications such as clinical toxicology, forensic analysis, or urine drug testing.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Digitek is a registered trademark of Mylan Bertek Pharmaceuticals, Inc.
Lanoxin is a registered trademark of GlaxoSmithKline LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

wgk_germany

WGK 2

flash_point_f

49.5 °F

flash_point_c

9.7 °C

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 5

1 of 5

NG-Hydroxy-L-arginine acetate salt

Sigma-Aldrich

H7278

NG-Hydroxy-L-arginine acetate salt

Phenytoin solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

P-063

Phenytoin solution

Digitoxin European Pharmacopoeia (EP) Reference Standard

D1800000

Digitoxin

2′-Deoxycytidine 5′-diphosphate sodium salt ≥96%

Sigma-Aldrich

D7250

2′-Deoxycytidine 5′-diphosphate sodium salt

Acetaminophen-D4 solution 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

P-909

Acetaminophen-D4 solution

Prescrire international, 22(137), 98-98 (2013-05-11)
Several epidemiological studies, some of which included several thousand women, have shown a link between digoxin exposure and the risk of breast cancer. A cohort study of women with angina, identified in the Danish Prescription Registry, showed a statistically significant
Acute rate control in atrial fibrillation with left ventricular dysfunction.
Shin-ichi Momomura
Circulation journal : official journal of the Japanese Circulation Society, 77(4), 893-894 (2013-03-19)
When 'digoxin use' is not the same as 'digoxin use': lessons from the AFFIRM trial.
Sabina A Murphy
European heart journal, 34(20), 1465-1467 (2013-04-18)
Ryozo Nagai et al.
Circulation journal : official journal of the Japanese Circulation Society, 77(4), 908-916 (2013-03-19)
A rapid heart rate (HR) during atrial fibrillation (AF) and atrial flutter (AFL) in left ventricular (LV) dysfunction often impairs cardiac performance. The J-Land study was conducted to compare the efficacy and safety of landiolol, an ultra-short-acting β-blocker, with those
Digoxin useful...with restrictions. Low doses for rhythm control may be safe, doctors say.
Harvard heart letter : from Harvard Medical School, 23(8), 6-6 (2013-08-07)
View All Related Papers

Protocols

LC/MS/MS Analysis of Interacting Cardiac Drugs Digoxin, Quinidine, Amiodarone and Verapamil on Titan™ C18

LC/MS/MS Analysis of Interacting Cardiac Drugs Digoxin, Quinidine, Amiodarone and Verapamil on Titan™ C18

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service